Lennox-Gastaut syndrome is a relatively rare epilepsy syndrome that usually 
begins in early-mid childhood and is characterized by multiple seizure types, 
particularly generalized seizures, which are often resistant to antiepileptic 
drug medication. Rufinamide is a new antiepileptic drug approved as adjunctive 
therapy to treat seizures in Lennox-Gastaut syndrome in those 4 years of age and 
older. In this article, the putative mechanism of action is described, along 
with data relating to its pharmacokinetics and metabolism. Key findings from 
clinical trials are presented and discussed. Adverse effects are summarized and 
compared with those encountered with competitor antiepileptic drugs. Finally, 
the role of rufinamide in the holistic management of subjects with 
Lennox-Gastaut syndrome is considered.